Clinical ocular manifestations of Taiwanese patients with mucopolysaccharidoses VI (Maroteaux–Lamy syndrome)

Mucopolysaccharidoses (MPS) is a group of lysosomal storage disorders that lead to accumulation of glycosaminoglycans (GAGs) in many tissues and organs, resulting in different clinical features. In this study, we conducted the manifestation changes of refractive error, corneal clouding, and intraocu...

Full description

Bibliographic Details
Main Authors: Hsu-Ying Lin, You-Hsin Huang, Shao-Yu Lei, Lee-Jen Chen, Shuan-Pei Lin
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Taiwan Journal of Ophthalmology
Subjects:
Online Access:http://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=3;spage=194;epage=197;aulast=Lin
id doaj-730d33dc5e524d84931c0b0c71ef64e8
record_format Article
spelling doaj-730d33dc5e524d84931c0b0c71ef64e82020-11-25T01:18:42ZengWolters Kluwer Medknow PublicationsTaiwan Journal of Ophthalmology2211-50562211-50722019-01-019319419710.4103/tjo.tjo_85_17Clinical ocular manifestations of Taiwanese patients with mucopolysaccharidoses VI (Maroteaux–Lamy syndrome)Hsu-Ying LinYou-Hsin HuangShao-Yu LeiLee-Jen ChenShuan-Pei LinMucopolysaccharidoses (MPS) is a group of lysosomal storage disorders that lead to accumulation of glycosaminoglycans (GAGs) in many tissues and organs, resulting in different clinical features. In this study, we conducted the manifestation changes of refractive error, corneal clouding, and intraocular pressure in two Taiwanese MPS VI patients with enzyme replacement therapy (ERT) initiated at the age of eight. In case 1, hyperopia was noted before and after ERT. Clinical observation showed no significant improvement in corneal clouding after ERT. In case 2, hyperopia was also noted initially before ERT and unable to be measured due to severe corneal opacity. Clinical observation showed no significant improvement in corneal clouding in after ERT, and the best-corrected visual acuity worsen and keratoplasty was needed in both eyes. Case 2 also had ocular hypertension and suspect MPS VI-related. However, due to severe corneal clouding, optic disc changes were hard to examine, and visual field was unable to be tested. Although some literature shows that ERT may be effective in preventing and/or clearing corneal stromal GAGs, accumulation and the timing of treatment initiation cloud be a clinical prognosis predictor; in this experience, no significant improvement of corneal clouding was observed in patients with MPS IV after ERT. Hyperopia and glaucoma were noted, and showed no changes after ERT. Severe corneal clouding can lead to difficulties in diagnosis and monitoring of hyperopia and glaucoma.http://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=3;spage=194;epage=197;aulast=LinCorneal cloudingenzyme replacement therapymucopolysaccharidosis VIrefractive error
collection DOAJ
language English
format Article
sources DOAJ
author Hsu-Ying Lin
You-Hsin Huang
Shao-Yu Lei
Lee-Jen Chen
Shuan-Pei Lin
spellingShingle Hsu-Ying Lin
You-Hsin Huang
Shao-Yu Lei
Lee-Jen Chen
Shuan-Pei Lin
Clinical ocular manifestations of Taiwanese patients with mucopolysaccharidoses VI (Maroteaux–Lamy syndrome)
Taiwan Journal of Ophthalmology
Corneal clouding
enzyme replacement therapy
mucopolysaccharidosis VI
refractive error
author_facet Hsu-Ying Lin
You-Hsin Huang
Shao-Yu Lei
Lee-Jen Chen
Shuan-Pei Lin
author_sort Hsu-Ying Lin
title Clinical ocular manifestations of Taiwanese patients with mucopolysaccharidoses VI (Maroteaux–Lamy syndrome)
title_short Clinical ocular manifestations of Taiwanese patients with mucopolysaccharidoses VI (Maroteaux–Lamy syndrome)
title_full Clinical ocular manifestations of Taiwanese patients with mucopolysaccharidoses VI (Maroteaux–Lamy syndrome)
title_fullStr Clinical ocular manifestations of Taiwanese patients with mucopolysaccharidoses VI (Maroteaux–Lamy syndrome)
title_full_unstemmed Clinical ocular manifestations of Taiwanese patients with mucopolysaccharidoses VI (Maroteaux–Lamy syndrome)
title_sort clinical ocular manifestations of taiwanese patients with mucopolysaccharidoses vi (maroteaux–lamy syndrome)
publisher Wolters Kluwer Medknow Publications
series Taiwan Journal of Ophthalmology
issn 2211-5056
2211-5072
publishDate 2019-01-01
description Mucopolysaccharidoses (MPS) is a group of lysosomal storage disorders that lead to accumulation of glycosaminoglycans (GAGs) in many tissues and organs, resulting in different clinical features. In this study, we conducted the manifestation changes of refractive error, corneal clouding, and intraocular pressure in two Taiwanese MPS VI patients with enzyme replacement therapy (ERT) initiated at the age of eight. In case 1, hyperopia was noted before and after ERT. Clinical observation showed no significant improvement in corneal clouding after ERT. In case 2, hyperopia was also noted initially before ERT and unable to be measured due to severe corneal opacity. Clinical observation showed no significant improvement in corneal clouding in after ERT, and the best-corrected visual acuity worsen and keratoplasty was needed in both eyes. Case 2 also had ocular hypertension and suspect MPS VI-related. However, due to severe corneal clouding, optic disc changes were hard to examine, and visual field was unable to be tested. Although some literature shows that ERT may be effective in preventing and/or clearing corneal stromal GAGs, accumulation and the timing of treatment initiation cloud be a clinical prognosis predictor; in this experience, no significant improvement of corneal clouding was observed in patients with MPS IV after ERT. Hyperopia and glaucoma were noted, and showed no changes after ERT. Severe corneal clouding can lead to difficulties in diagnosis and monitoring of hyperopia and glaucoma.
topic Corneal clouding
enzyme replacement therapy
mucopolysaccharidosis VI
refractive error
url http://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=3;spage=194;epage=197;aulast=Lin
work_keys_str_mv AT hsuyinglin clinicalocularmanifestationsoftaiwanesepatientswithmucopolysaccharidosesvimaroteauxlamysyndrome
AT youhsinhuang clinicalocularmanifestationsoftaiwanesepatientswithmucopolysaccharidosesvimaroteauxlamysyndrome
AT shaoyulei clinicalocularmanifestationsoftaiwanesepatientswithmucopolysaccharidosesvimaroteauxlamysyndrome
AT leejenchen clinicalocularmanifestationsoftaiwanesepatientswithmucopolysaccharidosesvimaroteauxlamysyndrome
AT shuanpeilin clinicalocularmanifestationsoftaiwanesepatientswithmucopolysaccharidosesvimaroteauxlamysyndrome
_version_ 1725141023251759104